Novel Drug Cuts Proteinuria in APOL1-Mediated Kidney Disease
An investigative treatment targeting APOL1 activity significantly improved proteinuria APOL1-mediated kidney disease (AMKD), a proof-of-concept phase IIa study found. In a single-arm, open-label study, treatment with oral VX-147 — a small molecule acting as an APOL1 function inhibitor — significantly reduced urine protein to creatinine ratio (UPCR) by 47.6% (95% CI -60 to -31.3%) by […]